magnesium chloride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4200	7786-30-3

Description:

Molecule	Description
Synonyms: magnesium chloride	Magnesium chloride. An inorganic compound consisting of one magnesium and two chloride ions. The compound is used in medicine as a source of magnesium ions, which are essential for many cellular activities. It has also been used as a cathartic and in alloys. Molecular weight: 95.21 Formula: Cl2Mg CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

magnesium chloride

Magnesium chloride. An inorganic compound consisting of one magnesium and two chloride ions. The compound is used in medicine as a source of magnesium ions, which are essential for many cellular activities. It has also been used as a cathartic and in alloys.

Molecular weight: 95.21
Formula: Cl2Mg
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.50	g	O
0.80	g	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 13, 1975	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	672.79	18.76	436	5573	324943	50274172
Peritonitis bacterial	543.47	18.76	123	5886	4538	50594577
Peritonitis	367.69	18.76	116	5893	15370	50583745
Peritoneal dialysis complication	346.85	18.76	67	5942	1114	50598001
Toxic anterior segment syndrome	339.86	18.76	69	5940	1496	50597619
Fungal peritonitis	227.48	18.76	41	5968	456	50598659
Device interaction	167.32	18.76	28	5981	193	50598922
Sepsis	144.22	18.76	122	5887	132803	50466312
Endophthalmitis	136.30	18.76	37	5972	2879	50596236
Encapsulating peritoneal sclerosis	91.97	18.76	18	5991	320	50598795
Ultrafiltration failure	88.09	18.76	16	5993	186	50598929
Peritoneal cloudy effluent	65.57	18.76	11	5998	77	50599038
Hypervolaemia	63.81	18.76	39	5970	25460	50573655
Cardiac disorder	53.87	18.76	43	5966	42936	50556179
Cardiovascular disorder	51.36	18.76	25	5984	10429	50588686
Post procedural complication	50.80	18.76	28	5981	15076	50584039
Tonsillar haemorrhage	48.36	18.76	10	5999	237	50598878
Anterior chamber inflammation	46.65	18.76	10	5999	283	50598832
Cardiac arrest	45.83	18.76	53	5956	83598	50515517
Myocardial infarction	44.79	18.76	54	5955	88973	50510142
Drug ineffective	43.06	18.76	22	5987	819311	49779804
Bloody peritoneal effluent	41.85	18.76	7	6002	48	50599067
Gangrene	41.69	18.76	17	5992	4675	50594440
Cardiac failure	39.69	18.76	47	5962	75993	50523122
Marasmus	37.40	18.76	9	6000	431	50598684
Cataract operation complication	36.23	18.76	7	6002	116	50598999
Cerebrovascular accident	33.03	18.76	48	5961	94632	50504483
Hypoglycaemia	32.83	18.76	36	5973	53545	50545570
Anterior chamber disorder	32.13	18.76	6	6003	82	50599033
Diabetic complication	27.59	18.76	8	6001	790	50598325
Hypoglycaemic coma	26.15	18.76	10	5999	2323	50596792
Noninfectious peritonitis	23.48	18.76	5	6004	137	50598978
Pulmonary oedema	23.47	18.76	29	5980	48909	50550206
Pneumonia	22.81	18.76	97	5912	378304	50220811
Dermatitis exfoliative	21.42	18.76	11	5998	5131	50593984
Abdominal distension	21.22	18.76	34	5975	72869	50526246
Faeces soft	20.76	18.76	10	5999	4074	50595041
Hypotension	20.53	18.76	68	5941	235401	50363714
Catheter site infection	20.30	18.76	10	5999	4276	50594839
Diabetic foot	19.77	18.76	7	6002	1311	50597804
Corneal oedema	19.42	18.76	7	6002	1380	50597735
Joint swelling	19.36	18.76	3	6006	245283	50353832
Blood glucose false positive	19.29	18.76	3	6006	12	50599103
Amylase abnormal	19.29	18.76	3	6006	12	50599103
Rash pruritic	19.26	18.76	26	5983	47820	50551295

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Peritonitis bacterial	774.79	24.76	190	6028	5566	29562743
Death	761.47	24.76	597	5621	341487	29226822
Peritonitis	487.18	24.76	163	6055	14661	29553648
Peritoneal dialysis complication	465.08	24.76	99	6119	1498	29566811
Fungal peritonitis	326.01	24.76	64	6154	628	29567681
Toxic anterior segment syndrome	283.25	24.76	61	6157	975	29567334
Device interaction	136.67	24.76	30	6188	525	29567784
Cardiac disorder	111.81	24.76	79	6139	37184	29531125
Encapsulating peritoneal sclerosis	108.21	24.76	25	6193	556	29567753
Myocardial infarction	107.91	24.76	124	6094	110172	29458137
Ultrafiltration failure	107.82	24.76	20	6198	140	29568169
Cardiac failure	96.39	24.76	100	6118	79187	29489122
Gangrene	90.96	24.76	34	6184	4184	29564125
Peritoneal cloudy effluent	85.28	24.76	16	6202	120	29568189
Noninfectious peritonitis	79.89	24.76	15	6203	113	29568196
Hypervolaemia	79.01	24.76	48	6170	17497	29550812
Post procedural complication	75.70	24.76	39	6179	10350	29557959
Sepsis	74.23	24.76	118	6100	142564	29425745
Cardiac arrest	73.29	24.76	90	6128	85501	29482808
Endophthalmitis	72.70	24.76	26	6192	2822	29565487
Cardiovascular disorder	57.86	24.76	31	6187	8904	29559405
Catheter site infection	57.38	24.76	20	6198	2012	29566297
Cataract operation complication	47.24	24.76	10	6208	146	29568163
Bloody peritoneal effluent	45.21	24.76	9	6209	95	29568214
Drug ineffective	44.39	24.76	11	6207	363159	29205150
Peritoneal effluent abnormal	38.66	24.76	7	6211	42	29568267
Hernia	32.88	24.76	21	6197	8337	29559972
Blood glucose false positive	31.98	24.76	6	6212	45	29568264
Cerebrovascular accident	31.12	24.76	57	6161	76854	29491455
Localised infection	29.62	24.76	24	6194	13792	29554517
Procedural pain	28.24	24.76	15	6203	4229	29564080
Keratitis	26.96	24.76	10	6208	1202	29567107
Peritoneal disorder	26.82	24.76	7	6211	261	29568048
Toxicity to various agents	26.11	24.76	3	6215	173658	29394651
Drug interaction	26.03	24.76	5	6213	197380	29370929
Complication associated with device	25.42	24.76	15	6203	5176	29563133

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Peritonitis bacterial	1040.30	17.46	240	8174	8803	64481515
Toxic anterior segment syndrome	557.57	17.46	114	8300	2325	64487993
Peritonitis	546.92	17.46	180	8234	24843	64465475
Peritoneal dialysis complication	484.97	17.46	100	8314	2128	64488190
Death	441.89	17.46	417	7997	482288	64008030
Fungal peritonitis	334.77	17.46	64	8350	907	64489411
Device interaction	240.56	17.46	46	8368	652	64489666
Endophthalmitis	199.10	17.46	58	8356	5307	64485011
Encapsulating peritoneal sclerosis	161.86	17.46	34	8380	791	64489527
Peritoneal cloudy effluent	104.20	17.46	19	8395	204	64490114
Ultrafiltration failure	102.11	17.46	19	8395	230	64490088
Sepsis	101.59	17.46	137	8277	230204	64260114
Post procedural complication	91.55	17.46	48	8366	21305	64469013
Gangrene	88.40	17.46	34	8380	7304	64483014
Cataract operation complication	87.67	17.46	17	8397	260	64490058
Cardiac arrest	84.18	17.46	102	8312	153962	64336356
Noninfectious peritonitis	70.97	17.46	14	8400	235	64490083
Hypervolaemia	70.30	17.46	50	8364	38235	64452083
Myocardial infarction	64.57	17.46	93	8321	165728	64324590
Cardiac disorder	63.63	17.46	55	8359	55761	64434557
Blood glucose false positive	55.73	17.46	9	8405	43	64490275
Drug ineffective	52.74	17.46	22	8392	840225	63650093
Bloody peritoneal effluent	51.20	17.46	10	8404	159	64490159
Catheter site infection	46.63	17.46	20	8394	5673	64484645
Cardiac failure	45.41	17.46	70	8344	132303	64358015
Complication associated with device	40.56	17.46	25	8389	15055	64475263
Hypoglycaemia	38.78	17.46	53	8361	89839	64400479
Peritoneal effluent abnormal	36.29	17.46	6	8408	34	64490284
Abdominal distension	34.65	17.46	52	8362	95942	64394376
Anterior chamber disorder	34.42	17.46	7	8407	138	64490180
Drug interaction	33.47	17.46	4	8410	362079	64128239
Peritoneal disorder	33.09	17.46	9	8405	640	64489678
Diabetic complication	32.11	17.46	10	8404	1145	64489173
Tonsillar haemorrhage	30.48	17.46	7	8407	248	64490070
Procedural complication	30.18	17.46	16	8398	7249	64483069
Toxicity to various agents	29.12	17.46	6	8408	363507	64126811
Rash pruritic	28.06	17.46	36	8378	57368	64432950
Pneumonia	27.82	17.46	145	8269	559431	63930887
Hypoglycaemic coma	25.40	17.46	12	8402	4262	64486056
Keratitis	25.29	17.46	11	8403	3226	64487092
Multimorbidity	24.97	17.46	8	8406	1004	64489314
Rash erythematous	24.56	17.46	31	8383	48602	64441716
Lactobacillus test positive	23.22	17.46	4	8410	30	64490288
Corneal disorder	23.02	17.46	9	8405	2018	64488300
Blood loss anaemia	22.88	17.46	17	8397	13875	64476443
Haemodialysis	21.85	17.46	18	8396	17059	64473259
Corneal oedema	21.75	17.46	9	8405	2334	64487984
Amylase abnormal	21.68	17.46	4	8410	46	64490272
Cerebrovascular accident	21.33	17.46	52	8362	137531	64352787
Device related infection	21.28	17.46	23	8391	30603	64459715
Peritoneal fluid analysis abnormal	20.96	17.46	4	8410	56	64490262
Staphylococcal infection	20.52	17.46	29	8385	50649	64439669
Failure to thrive	20.04	17.46	14	8400	10390	64479928
Eastern Cooperative Oncology Group performance status worsened	19.49	17.46	7	8407	1241	64489077
Regurgitation	19.24	17.46	8	8406	2101	64488217
Product complaint	18.30	17.46	14	8400	11940	64478378
Intraocular pressure increased	17.95	17.46	12	8402	8290	64482028
Dermatitis exfoliative	17.80	17.46	13	8401	10339	64479979
Peritoneal effluent leukocyte count increased	17.48	17.46	3	8411	22	64490296

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A12CC01	ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS OTHER MINERAL SUPPLEMENTS Magnesium
ATC	B05XA11	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Electrolyte solutions

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypomagnesemia	indication	190855004
Anuria	contraindication	2472002	DOID:2983
Hypocalcemia	contraindication	5291005
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Complete atrioventricular block	contraindication	27885002
Sarcoidosis	contraindication	31541009	DOID:11335
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Congenital myotonia, autosomal dominant form	contraindication	57938005
Acute nephropathy	contraindication	58574008
Diarrhea	contraindication	62315008
Hypercalcemia	contraindication	66931009	DOID:12678
Hypermagnesemia	contraindication	66978005
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Hyperchloremia	contraindication	74450001
Third degree burn injury	contraindication	80247002
Oliguria	contraindication	83128009
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hyporeninemic hypoaldosteronism	contraindication	236464008
Familial hyperkalemic periodic paralysis	contraindication	304737009	DOID:14451
Azotemia	contraindication	445009001
Severe dehydration	contraindication	450316000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	NORMOCARB HF 25	DIALYSIS SUPS	N021910	July 26, 2006	RX	SOLUTION	INJECTION	7300674	March 4, 2023	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	BAXTER HLTHCARE CORP	N207026	Jan. 13, 2015	RX	INJECTABLE	INJECTION	Jan. 13, 2022	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	BAXTER HLTHCARE CORP	N207026	Jan. 13, 2015	RX	INJECTABLE	INJECTION	Jan. 13, 2022	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES

Bioactivity Summary:

None

External reference:

ID	Source
4018213	VUID
N0000146546	NUI
D04834	KEGG_DRUG
4018213	VANDF
C0024472	UMLSCUI
CHEBI:86345	CHEBI
CHEMBL2219642	ChEMBL_ID
CHEMBL3185229	ChEMBL_ID
D015636	MESH_DESCRIPTOR_UI
DB09407	DRUGBANK_ID
02F3473H9O	UNII
46835706	PUBCHEM_CID
6579	RXNORM
5007	MMSL
5009	MMSL
71973	MMSL
d03796	MMSL
000786	NDDF
45733002	SNOMEDCT_US
768454005	SNOMEDCT_US
7791-18-6	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	0.30 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	0.30 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-1795	SOLUTION	0.30 mg	OPHTHALMIC	NDA	9 sections
HyperlyteCR	HUMAN PRESCRIPTION DRUG LABEL	5	0264-1943	INJECTION, SOLUTION, CONCENTRATE	0.51 g	INTRAVENOUS	UNAPPROVED DRUG OTHER	18 sections
HyperlyteCR	HUMAN PRESCRIPTION DRUG LABEL	5	0264-1943	INJECTION, SOLUTION, CONCENTRATE	0.51 g	INTRAVENOUS	UNAPPROVED DRUG OTHER	18 sections
Balanced Salt	HUMAN PRESCRIPTION DRUG LABEL	6	0264-1945	SOLUTION	0.30 mg	IRRIGATION	ANDA	11 sections
Physiolyte	HUMAN PRESCRIPTION DRUG LABEL	5	0264-2205	IRRIGANT	0.03 g	IRRIGATION	NDA	20 sections
Physiolyte	HUMAN PRESCRIPTION DRUG LABEL	5	0264-2205	IRRIGANT	0.03 g	IRRIGATION	NDA	20 sections
Balanced Salt	HUMAN PRESCRIPTION DRUG LABEL	6	0264-2514	SOLUTION	0.30 mg	IRRIGATION	ANDA	11 sections
Isolyte S	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7703	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	19 sections
Isolyte S	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7703	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	19 sections
Isolyte S pH 7.4	HUMAN PRESCRIPTION DRUG LABEL	7	0264-7707	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	24 sections
Isolyte S pH 7.4	HUMAN PRESCRIPTION DRUG LABEL	7	0264-7707	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	24 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Dextrose and Electrolyte No. 48	HUMAN PRESCRIPTION DRUG LABEL	6	0338-0143	INJECTION	31 mg	INTRAVENOUS	NDA	19 sections
Dextrose and Electrolyte No. 48	HUMAN PRESCRIPTION DRUG LABEL	6	0338-0143	INJECTION	31 mg	INTRAVENOUS	NDA	19 sections
Plasma-Lyte 148	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0179	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	20 sections
Plasma-Lyte 148	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0179	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
Plasma-Lyte A	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0221	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	19 sections
Plasma-Lyte A	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0221	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	19 sections
Cardioplegic	HUMAN PRESCRIPTION DRUG LABEL	4	0338-0341	SOLUTION	325.30 mg	INTRA-ARTERIAL	ANDA	15 sections